因无法按期发布2025年度经审核业绩,专注分子诊断领域的新加坡上市企业Mirxes觅瑞(简称“觅瑞”)被港交所实施停牌。4月30日,觅瑞发布公告披露,其于4月27日收到香港联合交易所有限公司发出的复牌指引函件,列明六项纠正及证明事项,其股份将继续暂停买卖直至另行通知。这是觅瑞自4月1日停牌以来与港交所之间的首次正式制度性回应,公司接下来的工作重心已明确指向合规整改与信息披露。 根据公告,港交所...
Source Link因无法按期发布2025年度经审核业绩,专注分子诊断领域的新加坡上市企业Mirxes觅瑞(简称“觅瑞”)被港交所实施停牌。4月30日,觅瑞发布公告披露,其于4月27日收到香港联合交易所有限公司发出的复牌指引函件,列明六项纠正及证明事项,其股份将继续暂停买卖直至另行通知。这是觅瑞自4月1日停牌以来与港交所之间的首次正式制度性回应,公司接下来的工作重心已明确指向合规整改与信息披露。 根据公告,港交所...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.